Shanghai Helioson Pharmaceutical Co. Ltd. has identified molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1) and/or zinc finger protein Aiolos (IKZF3) degradation inducers reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Insilico Medicine Inc. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of obesity, autoimmune disease and inflammatory disorders.
Cellus Inc. has disclosed compounds acting as disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) and 5 (ADAMTS5; aggrecanase-2) inhibitors reported to be useful for the treatment of septic arthritis, osteoarthritis, osteonecrosis, rheumatoid arthritis and tuberculosis.
Recent advances in the management of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, have shown that inhibiting the interaction between the α4β7 integrin and the endothelial ligand mucosal addressin cell adhesion molecule 1 (MADCAM1) has proven useful, safe and effective.
Currently, there are no specific antiviral drugs available for treating hepatitis E virus (HEV) infection, which represents a global health burden, causing acute viral hepatitis with varying clinical outcomes.
Researchers from Nitrase Therapeutics Inc. recently presented preclinical findings on NTX-101, a murine chimeric antibody designed to specifically bind to nitrated tyrosine on α-synuclein (α-Syn). It was demonstrated that NTX-101 bound both chemically and synthetically nitrated α-Syn (n-Syn), with no binding to non-nitrated α-Syn or an irrelevant nitrated protein observed.
More than half of all hearing loss cases are hereditary. Myelin protein zero-like 2, encoded by MPZL2, is widely expressed in cochlear cells in the inner ear. Mutations in MPZL2 have been identified as the second most prevalent cause of mild to moderate hereditary hearing loss.
Graft Polymer (UK) plc has announced a research agreement between its partner, Awakn Life Sciences Corp., and the University of Nottingham. The agreement covers in vivo research to evaluate the potential of Graft Polymer and Awakn’s aminoindane NCE co-lead series to enhance social cognition and pro-social behaviors.
At the United European Gastroenterology Week in Vienna, Redx Pharma plc presented data regarding their ROCK inhibitor RXC-008 for treating fibrostenotic Crohn’s disease. RXC-008 is restricted to the gastrointestinal tract, thus avoiding systemic exposure; ROCK1/2 kinases are involved in fibrosis and their blockade has been efficacious in several rodent models of fibrotic disease.
RSS
